Richard Jirui Lin

2000 University of California, San Diego, La Jolla, CA 
"Richard Lin"
Mean distance: 17.34 (cluster 11)


Sign in to add mentor
Ronald M. Evans grad student 2000 UCSD
 (Transcriptional silencing in the molecular pathogenesis of acute promyelocytic leukemia.)
BETA: Related publications


You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Lin RJ, Baser RE, Elko TA, et al. (2020) Geriatric syndromes in 2-year, progression-free survivors among older recipients of allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation
Olin RL, Fretham C, Pasquini MC, et al. (2020) Geriatric assessment in older alloHCT recipients: association of functional and cognitive impairment with outcomes. Blood Advances. 4: 2810-2820
Lin RJ, Ho C, Devlin SM, et al. (2020) Impact of allogeneic hematopoietic cell transplantation on immune evasive mechanisms in relapsed refractory large B-cell lymphoma. Bone Marrow Transplantation
Lin RJ, Michaud L, Lobaugh SM, et al. (2020) The geriatric syndrome of sarcopenia impacts allogeneic hematopoietic cell transplantation outcomes in older lymphoma patients. Leukemia & Lymphoma. 1-9
Lin RJ, Cohen AG, Stabler SM, et al. (2020) Characteristics and Impact of Post-Transplant Interdisciplinary Palliative Care Consultation in Older Allogeneic Hematopoietic Cell Transplant Recipients. Journal of Palliative Medicine
Peled JU, Gomes ALC, Devlin SM, et al. (2020) Microbiota as Predictor of Mortality in Allogeneic Hematopoietic-Cell Transplantation. The New England Journal of Medicine. 382: 822-834
Lin RJ, Lobaugh SM, Pennisi M, et al. (2020) Impact and safety of chimeric antigen receptor T cell therapy in older, vulnerable patients with relapsed/refractory large b-cell lymphoma. Haematologica
Pennisi M, Cho C, Devlin SM, et al. (2020) Don't Let the HCT-CI Fool You: Similar Outcomes with Myeloablative CD34+ Selected Allo-HCT Compared to Unmodified RIC Allo-HCT in Patients with AML or MDS and High Comorbidity Scores. Biology of Blood and Marrow Transplantation. 26
Shouval R, Fein JA, Devlin SM, et al. (2020) The Impact of Individual Co-Morbidities in Myeloablative Ex Vivo CD34+ Selected Allogeneic Hematopoietic Cell Transplantation Biology of Blood and Marrow Transplantation. 26: S141
Brambilla CZ, Ruiz JD, Lobaugh SM, et al. (2020) Long-Term Survival in Patients with AML or MDS Relapsed after Allogeneic Hematopoietic Cell Transplantation: Importance of Second Cell Therapy Biology of Blood and Marrow Transplantation. 26: S97-S98
See more...